Anixa Biosciences (NASDAQ:ANIX) Cut to Sell at Wall Street Zen

Anixa Biosciences (NASDAQ:ANIX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

ANIX has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, February 4th. Finally, Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.00.

Anixa Biosciences Stock Down 1.0%

Shares of NASDAQ:ANIX opened at $2.83 on Friday. The firm has a fifty day moving average of $3.03 and a two-hundred day moving average of $3.55. Anixa Biosciences has a 12-month low of $2.33 and a 12-month high of $5.46. The firm has a market capitalization of $94.89 million, a P/E ratio of -8.58 and a beta of 0.48.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Equities research analysts expect that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Arnold M. Baskies bought 10,000 shares of the stock in a transaction that occurred on Wednesday, January 28th. The shares were acquired at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the purchase, the director owned 135,000 shares of the company’s stock, valued at $410,400. This represents a 8.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Anixa Biosciences by 2.1% in the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock valued at $4,694,000 after purchasing an additional 29,436 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Anixa Biosciences by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after purchasing an additional 7,271 shares during the last quarter. Bank of America Corp DE boosted its stake in Anixa Biosciences by 1.7% during the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after purchasing an additional 3,645 shares during the period. State Street Corp boosted its stake in Anixa Biosciences by 32.0% during the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock valued at $496,000 after purchasing an additional 38,540 shares during the period. Finally, 683 Capital Management LLC acquired a new stake in Anixa Biosciences in the 4th quarter valued at approximately $355,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.